Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

被引：8
|
作者：
Sonneveld, Pieter
Asselberg-Hacker, Emilie
Zweegman, Sonja
van der Holt, Bronno
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.688.688
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
688
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network
    Sonneveld, Pieter
    Asselbergs, Emilie
    Van der Holt, Bronno
    Zweegman, Sonja
    Kerstens, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk
    BLOOD, 2014, 124 (21)
  • [2] Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial
    Wester, Ruth
    van der Holt, Bronno
    Asselbergs, Emelie
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    Kooij, Marinus van Marwijk
    de Weerdt, Okke
    Minnema, Monique C.
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk M.
    Broyl, Annemiek
    Iskander, Karim Saad
    Sonneveld, Pieter
    BLOOD, 2017, 130
  • [3] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
    Wester, Ruth
    van der Holt, Bronno
    Asselbergs, Emelie
    van Duin, Mark
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    Kooy, Marinus van Marwijk
    de Weerdt, Okke
    Minnema, Monique
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk M.
    Broijl, Annemiek
    Sonneveld, Pieter
    BLOOD, 2016, 128 (22)
  • [4] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
    Wester, Ruth
    van der Holt, Bronno
    Asselbergs, Emelie
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    Kooy, Marinus van Marwijk
    de Weerdt, Okke
    Minnema, Monique
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk
    Broijl, Annemiek
    Sonneveld, Pieter
    HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273
  • [5] Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
    Wester, Ruth
    Zweegman, Sonja
    van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    Asselbergs, Emelie
    de Weerdt, Okke
    Minnema, Monique C.
    Lonergan, Sarah
    Palumbo, Antonio
    Broijl, Annemiek
    Sonneveld, Pieter
    HEMASPHERE, 2020, 4 (04):
  • [6] Low-dose thalidomide in patients with advanced, refractory multiple myeloma.
    Chen, CI
    Adesanya, A
    Sutton, DM
    Brandwein, J
    Stewart, AK
    BLOOD, 1999, 94 (10) : 308B - 308B
  • [7] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
    Dytfeld, Dominik
    Jasielec, Jagoda
    Griffith, Kent A.
    Lebovic, Daniel
    Vesole, David H.
    Jagannath, Sundar
    Al-Zoubi, Ammar
    Anderson, Tara
    Detweiler-Short, Kristen
    Stockerl-Goldstein, Keith
    Ahmed, Asra
    Jobkar, Terri
    Durecki, Diane E.
    McDonnell, Kathryn
    Mietzel, Melissa
    Couriel, Daniel
    Kaminski, Mark
    Vij, Ravi
    Jakubowiak, Andrzej J.
    HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
  • [8] Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHA-DEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients With Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN
    Sonneveld, Pieter
    Hacker, Emilie
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk M.
    BLOOD, 2011, 118 (21) : 290 - 290
  • [9] Treatment of newly diagnosed, inner-city multiple myeloma patients with zoledronate, dexamethasone, and low-dose thalidomide: A phase II trial.
    Klueppelberg, Uwe
    Smith, Eric L. P.
    Braunstein, Marc J.
    Kahn, David
    Batuman, Olcay A.
    BLOOD, 2006, 108 (11) : 371B - 371B
  • [10] Phase III trial of thalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 452 - 453
12345